Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
NCT ID: NCT02282579
Last Updated: 2018-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2014-10-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
NCT01577784
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
NCT01649778
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
NCT01513187
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
NCT01521715
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
NCT02324803
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with metastatic renal cell carcinoma treated
Patient with metastatic renal cell carcinoma treated with Pazopanib
Pazopanib
Non interventional study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pazopanib
Non interventional study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Metastatic renal cell cancer of any histology.
* Patients treated with pazopanib for metastatic cell renal cancer outside the context of clinical trials (clinical practice) in Spanish centers from 1 April 2011 until 30 June 2014. shall be included all patients who received pazopanib as first-line treatment in each participating center, whether had experienced treatment failure with pazopanib or were still in first-line treatment. The inclusion of patients who are also allowed received cytokine as first-line treatment followed by pazopanib as well as patients who received sunitinib as first-line treatment and have changed pazopanib for toxicity or intolerance, provided they have not received more a cycle of sunitinib.
Exclusion Criteria
* Patients with the diagnosis and / or treatment of malignancies of importance other than Cell renal cancer.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Spanish Oncology Genito-Urinary Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Arranz, PhD
Role: PRINCIPAL_INVESTIGATOR
Investigator coordinator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Son Espases
Palma de Mallorca, Mallorca, Spain
Hospital Clínic de Barcelona
Barcelona, , Spain
Hospital Vall d' Hebron
Barcelona, , Spain
Hospital San Pedro de Alcántara
Cáceres, , Spain
Hospital G U de Ciudad Real
Ciudad Real, , Spain
Hospital Reina Sofía
Córdoba, , Spain
Hospital Universitario de Donostia
Donostia / San Sebastian, , Spain
Hospital San Cecilio
Granada, , Spain
Hospital General Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, , Spain
Hospital de León
León, , Spain
Hospital San Pedro Logroño
Logroño, , Spain
Hospital Lucus Augusti
Lugo, , Spain
Hospital Gregorio Marañon
Madrid, , Spain
Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Clínico San Carlos
Madrid, , Spain
Hospital Quirón
Madrid, , Spain
Hospital U Puerta de Hierro Majadahonda
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Provincial de Pontevedra
Pontevedra, , Spain
Hospital Clínico Universitario Salamanca
Salamanca, , Spain
Hospital Universitario de Canarias
Santa Cruz de Tenerife, , Spain
Hospital Marques de Valdecilla
Santander, , Spain
Hospital Ntra. Sra. De Valme
Seville, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
Hospital Virgen de la Salud
Toledo, , Spain
Hospital Clínico de Valencia
Valencia, , Spain
Hospital Gral Universitario Valencia
Valencia, , Spain
Hospital Universitario Dr. Peset
Valencia, , Spain
IVO Valencia
Valencia, , Spain
Hospital Rio Hortega
Valladolid, , Spain
CHUVI ( Vigo)
Vigo, , Spain
Hospital Lozano Blesa
Zaragoza, , Spain
Hospital Miguel Servet
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SOG-SPA-2014-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.